Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Source filing unavailable
| Metric | Q3 2015 | Q3 2012 | Q3 2011 |
|---|---|---|---|
| Revenue | — | $148.26K | $26.59K |
| Net Income | -$2.92M | -$7.30M | $2.54M |
| EPS Diluted | -$0.10 | -$0.39 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
